#1 Clinical Trials Search in Europe

Study on Adding Trastuzumab and Pertuzumab to Treatment for Patients with Resectable HER2 Positive Esophageal Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer called HER2-positive esophageal adenocarcinoma. This is a cancer that affects the esophagus, which is the tube that carries food from the mouth to the stomach. The study is investigating the effects of adding two medications, trastuzumab and pertuzumab, to the usual treatment of chemotherapy and radiation before surgery. These medications are given as a solution through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to see if adding trastuzumab and pertuzumab can help improve the overall survival of patients with this type of cancer. Participants in the study will receive either the standard treatment or the standard treatment plus the two additional medications. Some participants may receive a placebo instead of the additional medications. The study will follow participants over a period of time to monitor their health and the effectiveness of the treatment.

Throughout the study, researchers will look at various outcomes, including how long patients live, how well the cancer responds to treatment, and the quality of life of the participants. The study will also assess the safety of the treatment by monitoring any side effects or complications that may occur. The goal is to gather information that could lead to better treatment options for people with HER2-positive esophageal adenocarcinoma in the future.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including age, tumor characteristics, and overall health status.

Written informed consent is required to participate in the study.

2 initial assessment

An initial assessment is conducted to evaluate the health status and confirm the presence of HER2 positive esophageal adenocarcinoma.

This includes various tests to ensure the patient is fit for the treatment plan.

3 treatment phase

The treatment involves the administration of two medications: trastuzumab and pertuzumab.

These medications are given as a solution for infusion, which means they are administered directly into the bloodstream through an intravenous infusion.

The specific dosage and frequency of administration are determined by the healthcare team based on individual patient needs.

4 monitoring and follow-up

Regular monitoring is conducted to assess the response to treatment and manage any side effects.

Follow-up appointments are scheduled to evaluate the progress and adjust the treatment plan if necessary.

5 completion of treatment

Upon completion of the treatment phase, a final assessment is conducted to determine the overall response to the therapy.

The study aims to improve overall survival and assess other outcomes such as quality of life and treatment safety.

Who Can Join the Study?

  • The patient must have a type of cancer called adenocarcinoma in the esophagus or where the esophagus meets the stomach. This cancer must be at a specific stage, either T1N+M0 or T2-T4a N0 or N+ M0.
  • The cancer must be HER2-positive, which means it has a specific protein that can be detected by tests. This is confirmed by a local lab and checked by a central lab.
  • The cancer must be able to be removed by surgery, as decided by a team of doctors. If the tumor is too large to be examined with a special tube called an endoscope, it can still be eligible if other conditions are met.
  • If the cancer spreads below the area where the esophagus meets the stomach, most of the tumor must still be in the esophagus or the junction area.
  • The patient must be at least 18 years old.
  • The patient must be healthy enough to undergo a surgery called esophagectomy, which involves removing part of the esophagus.
  • The patient must have good blood, kidney, and liver function, as shown by specific medical tests:
    • Neutrophils (a type of white blood cell) must be at least 1.5 x 109/L.
    • Platelets (cells that help blood clot) must be at least 100 x 109/L.
    • Hemoglobin (a protein in red blood cells) must be at least 5.6 mmol.
    • Total bilirubin (a substance made by the liver) must be no more than 1.5 times the normal limit.
    • Creatinine (a waste product in the blood) must be less than 150 μmol/L, or the creatinine clearance (a test of kidney function) must be at least 50 ml/min.
  • The patient must have a healthy heart, with a left ventricular ejection fraction (a measure of heart function) of at least 50%, determined by a heart ultrasound or a MUGA scan.
  • The patient must provide written, voluntary consent to participate in the study.
  • The patient must be able to attend follow-up appointments and receive treatment at the study center.

Who Cannot Join the Study?

  • Patients who do not have HER2 positive esophageal adenocarcinoma cannot participate. This is a specific type of cancer in the esophagus that tests positive for a protein called HER2.
  • Patients who are not within the specified age range cannot participate. The age range is typically defined in the study details.
  • Patients who are not able to undergo surgery to remove the cancer cannot participate. “Resectable” means the cancer can be surgically removed.
  • Patients who are not eligible for the standard treatment for this type of cancer cannot participate. “Standard of care” refers to the usual treatment given for a condition.
  • Patients who are part of a vulnerable population, such as those unable to give consent, are not included in this study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Zuyderland Medisch Centrum Stichting Geleen The Netherlands
Frisius Heerenveen The Netherlands
Holland Protonen Therapie Centrum Delft The Netherlands

Other Sites

Site Name City Country Status
Noordwest Ziekenhuisgroep Stichting Alkmaar The Netherlands
Stichting Viecuri Medisch Centrum voor Noord-Limburg Venlo The Netherlands
Medisch Spectrum Twente Enschede The Netherlands
Ziekenhuisgroep Twente Stichting Almelo The Netherlands
Dr. Bernard Verbeeten Instituut Stichting Tilburg The Netherlands
Maastro Maastricht The Netherlands
Flevoziekenhuis Stichting Almere The Netherlands
Universitair Medisch Centrum Utrecht Utrecht The Netherlands
Catharina Ziekenhuis Stichting Eindhoven The Netherlands
Stichting Radboud University Medical Center Nijmegen The Netherlands
Deventer Ziekenhuis Deventer The Netherlands
Reinier de Graaf Groep Delft The Netherlands
Medical Center Haaglanden Leidschendam The Netherlands
Bravis Ziekenhuis Roosendaal The Netherlands
Gelre Hospitals Zutphen The Netherlands
Netherlands Cancer Institute Amsterdam The Netherlands
Spaarne Gasthuis Hoofddorp The Netherlands
Dijklander Ziekenhuis Hoorn The Netherlands
Lijed Uvnhelfnkbhe Mwqfmub Cbbuyne (wdptt Leiden The Netherlands
Rnnwlraxw Zkohzmmzqa Shttzjqif Arnhem The Netherlands
Uzmzawlldqup Mpihfke Ciwqdji Garfnfbky Groningen The Netherlands
Aqqqvxka Dq Rlrxir Zseuidvksn Bgpr Goes The Netherlands
Zssvuilg Rasinethvxnbnpyxrm Izjupldyk Vlissingen The Netherlands
Rarfmpyazqrhpxhwty Anjrbt Arnhem The Netherlands
Rxxwxqnckepwrhkfpv Iaojwvjjd Fivvmzrcv Leeuwarden The Netherlands
Abcwqffei Ucc Amsterdam The Netherlands
Eoklchf Ucyqutzrxgzy Mtryoez Cvnrzdy Rumigedgf (odsyjvs Mro Rotterdam The Netherlands
Seh Eiblizguz Hlwxklru Tpjrtkm Tilburg The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Recruiting
03.01.2022

Trial locations

Investigated drugs:

Trastuzumab is a medication used in this trial to target and block the HER2 protein, which can promote the growth of cancer cells. By blocking this protein, trastuzumab helps to slow down or stop the growth of cancer cells in patients with HER2-positive esophageal adenocarcinoma.

Pertuzumab is another medication used in the trial that also targets the HER2 protein. It works in a similar way to trastuzumab but binds to a different part of the HER2 protein. When used together, pertuzumab and trastuzumab provide a more comprehensive blockade of the HER2 protein, potentially improving the effectiveness of the treatment in stopping cancer cell growth.

Investigated diseases:

HER2 Positive Esophageal Adenocarcinoma – This is a type of cancer that occurs in the esophagus, the tube that carries food from the throat to the stomach. It is characterized by the overexpression of the HER2 protein, which promotes the growth of cancer cells. This form of adenocarcinoma typically begins in the glandular cells of the esophagus and can lead to difficulty swallowing, weight loss, and chest pain as it progresses. The disease may spread to nearby lymph nodes and other parts of the body if not managed. It is often diagnosed in the later stages due to subtle early symptoms. The progression of the disease can vary, with some cases advancing more rapidly than others.

Trial ID:
2024-513797-22-00
NCT ID:
NCT05188313
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain

  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated drugs:
    Spain